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Voluntary informed consent for participation in clinical research 
is the cornerstone of health research ethics and a requirement 
for clinical research in South Africa. The South African-specific 
guidance documents concerning voluntary informed consent 
provisions differ and sometimes contradict international documents 
applicable in South Africa. With the provisions of the Constitution 
of South Africa (1996) and applicable legislation, it is apparent that 
voluntary informed consent provisions in the guidance documents 
are not always aligned with the relevant legislation and constitutional 
principles regarding informed consent. 
The SA GCP guideline (South African Guidelines for Good 
Practice in the Conduct of Clinical Trials with Human Participants 
in South Africa)1 requires that it should always apply even where it 
differs from the other guidance documents (at section 1.3, p. 12). 
However, is the SA GCP guideline the ultimate and correct authority 
regarding voluntary informed consent, and are its voluntary informed 
consent provisions in line with governing legislation and the supreme 
Constitution of South Africa of 1996? 
To ascertain the extent of similarities and differences in the 
guidance documents relevant to clinical research in South Africa, 
we compared the following documents: International Conference 
on Harmonisation: E6 Consolidated Guidelines for Good Clinical 
Practice, 1996 (ICH GCP);2 SA GCP 2006;1 Declaration of Helsinki 
(2004) as incorporated in SA GCP 2006 (World Medical Association 
at its 55th General Assembly, Tokyo, 2004);3 Declaration of Helsinki 
(2008) (World Medical Association at its 59th General Assembly, 
Seoul, 2008);4 Ethics in Health Research: Principles, Structures and 
Processes (Department of Health 2004 – ‘ethical guidelines’ for the 
purpose of this paper);5 the Constitution of the Republic of South 
Africa (1996);6 and the National Health Act 61 of 2003.7 The HPCSA’s 
booklet 6, General Ethical Guidelines for Health Researchers (2008),8 
although not discussed, provides valuable guidance on ethical 
behaviour in research.
Informed consent in South Africa 
contextualised
The doctrine of informed consent originated in 1957 in the case of 
Salgo v Leland Stanford Jr. University Board of Trustees 317 P.2d 170 
(Cal. Dist. Ct. App. 1957).9 This doctrine is about patient autonomy 
and self-determination and was first introduced in South Africa 
in 1976 in the case of Richter and another v Estate Hammann 1967 
(3) SA 226 (C).10 Seventeen years later, in Castell v De Greef 1994 
(4) SA 408 (C)11 the doctrine was secured in South African medical 
and health law jurisprudence.12 Self-determination and the rights to 
bodily integrity and autonomous moral agency are now accepted as 
fundamental rights of every patient, and it is also accepted that health 
workers have a legal duty to obtain a patient’s informed consent 
for any medical intervention. ‘The best interests of the patient’ 
cannot prevail above patient autonomy and self-determination, and 
informed consent requires a patient to fully appreciate the nature and 
extent of the harm or risk inherent in the intervention.11,12  
The doctrine of informed consent is codified in sections 6, 7 and 
8 of the National Health Act. The Act sets out the nature and scope 
of the information that should be disclosed to the patient, that it 
should be done in a language that the patient understands, and that 
the patient’s level of literacy should be taken into account. The Act 
provides for patients’ rights to self-determination and that their 
informed consent is required even if they were treated previously 
and the necessary consent was obtained then. It reiterates the right 
to self-determination that protects every person’s right to bodily and 
psychological integrity and the right to security and control over their 
body as enshrined in the Constitution (section 12). 
No judgment on informed consent has been handed down since 
the National Health Act was enacted. Cases in South African medical 
law, McDonald v Wroe 2006 (3) All SA 565 (C)13 and Louwrens 
v Oldwage 2006 (2) SA 161 (SCA),14 also pay no attention to the 
provisions of the National Health Act (then Bill). The National Health 
Act provides for research on or experimentation on human subjects 
and is therefore central to good practice in clinical trials. Sections 6, 8 
and 71 are important for informed consent in clinical trials. Informed 
consent and the constitutional right to self-determination in a clinical 
setting underscore the relationship between research participant and 
researcher. 
Voluntariness
Valid informed consent must be voluntary in clinical trials but can 
be influenced by two factors. The first is non-controlling factors 
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Most differences, shortcomings and contradictions regarding 
voluntary informed consent for participation in clinical research 
relate to the South African-specific guidance documents, i.e. 
South African Guidelines for Good Practice in the Conduct of 
Clinical Trials with Human Participants in South Africa (2006) 
and Ethics in Health Research: Principles, Structures and Processes 
(2004). These documents do not fulfil all the ethical and legal 
requirements for voluntary informed consent for clinical research 
participation in South Africa. International guidance documents 
reflect the minimum of the ethical requirements for the conduct of 
clinical research. Country-specific documents should be updated 
and aligned with relevant legislative and legal principles of that 
jurisdiction to ensure that research participants are adequately 
protected. The South African-specific guidance documents 
therefore require revision to address these deficiencies. 
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like pain, psychological factors such as altruism or social and 
economic situations like poverty. Prospective participants may also 
be influenced by the power difference between themselves and the 
research investigators that threaten truly voluntary, valid informed 
consent. Another factor is when a treatment option for a condition 
is only available as part of a research trial and is not available in 
the private or public health sectors. Truly voluntary participation 
in such a trial is questionable.15 Controlling factors that influence 
voluntariness include persuasion, manipulation and coercion to 
participate in research.16 
The influence of controlling factors on voluntary informed 
consent in clinical research and participatory decision-making 
deserves special attention in South Africa. Participatory decision-
making refers to situations where individuals other than the research 
participant partake in the decision whether the participant should 
enrol for the clinical research trial. The Declaration of Helsinki 2008 
explicitly provides for the participant to consult family members or 
community leaders on research participation. The ethical guidelines 
imply this communitarian world view that informed consent should 
be obtained with an ‘understanding of the participant’s world view or 
value system’. Yet, despite the opportunity of consulting with others, 
the prospective participant makes the final autonomous decision. 
Researchers should therefore respect the research participant’s 
decision to consult family members and community leaders and 
not assume that they have the same world view and values of their 
community.17 While the ethical guidelines recognise that community 
involvement should only be allowed with explicit consent of the 
prospective participant, no other guidance documents refer to this 
or address the potential risks and problems that may result because 
of participatory decision-making. Therefore, this shortcoming in the 
guidance documents requires attention as participatory decision-
making is especially important for clinical research in Africa and 
with indigenous communities. (The National Health Research Ethics 
Council (NHREC) issued separate guidelines in 2011 on the role 
of community advisory groups in health research ethics and how 
communities should be engaged in research.) 
A serious discrepancy in the SA GCP and ICH GCP compared 
with the general purport and object of voluntary informed consent 
in the National Health Act, in section 12 of the Constitution (1996) 
and in case law, deals with a research participant electing to withdraw 
from a clinical trial. The ICH GCP and SA GCP require that although 
a research participant is not obliged to give his/her reason(s) for 
withdrawing prematurely from a trial, the researcher should attempt 
to ascertain the reasons while fully respecting the participant’s rights. 
This requirement is a contradiction, as it does not fully respect the 
participant’s wishes and voluntary decision to withdraw from the 
clinical trial prematurely. The participant may feel threatened by the 
researcher attempting to obtain a reason for the withdrawal from the 
study, and may for this reason decide not to withdraw. Respect for 
participants and their autonomous rights do not end when they sign 
consent. Allowing a participant to decline consent or to withdraw 
from research participation without a reason is respectful of their 
rights.17 The GCPs in this regard contradict the notion of voluntary 
participation. 
Providing adequate information and 
the concept of being informed
Another difference in the guidance documents is that the Declaration 
of Helsinki 2004 and 2008 and the ethical guidelines (in section 2.6) 
require that the prospective participant understands (or comprehends) 
the provided information before deciding on participation. Pivotal 
for autonomy is the process to adequately inform prospective 
participants about the research and to assess their understanding 
of the information provided. Personal autonomy is self-rule that is 
free from controlling influences by others and limitations, such as 
inadequate understanding, that prevent a meaningful and informed 
choice.17 The GCPs, however, do not require comprehension by the 
participant. 
Ethically, for an action to be autonomous it must be substantially 
understood and full understanding of all aspects of the research is 
not needed.17 The minimum that should be understood is what the 
researcher believes a prospective participant should understand to 
authorise the action.17 A professional standard or medical judgement 
on whether adequate information was disclosed and whether the 
patient/participant truly comprehended is therefore the appropriate 
biomedical ethics standard. However, this is not sufficient in terms of 
South African (and international) legal precedent. 
Initially cases on informed consent did little to clarify the far-
reaching authority of physicians regarding their discretion when 
disclosing information to a patient or research participant. Whether 
adequate information was disclosed and the patient/participant 
truly comprehended remained a matter of medical judgement 
in which thorough patient self-determination had no place.18 In 
Castell v De Greef, however, a subjective patient-centred test for 
disclosure was used – a health worker or researcher should disclose 
all information and risks that a reasonable person in the patient’s/
prospective participant’s position would be able to attach significance 
to.11,19 
This subjective patient-centred test was affirmed in Broude v 
McIntosh 1998 (3) SA 60 (SCA)20 and McDonald v Wroe 2006 (3) 
All SA 565 (C). It is also incorporated in sections 6 - 8 and 71 of 
the National Health Act and is in line with the constitutional right 
to self-determination. However, the Supreme Court of Appeal erred 
in the case of Louwrens v Oldwage 2006 (1) All SA 197 (SCA) in 
that the subjective patient-centred test for disclosure was accepted 
in the court a quo, but the court of appeal applied the dictum 
from the 1976 Richter case which required a professional standard 
(medical judgement) for disclosure.19,21 A serious legal shortcoming 
of the GCPs is therefore their lack of address and general ignorance 
regarding the appropriate standard to be applied when considering 
whether adequate information was disclosed and whether that 
particular patient/participant truly understood the information 
before deciding on research participation. 
A once-off meeting with the researcher may be insufficient for the 
prospective participant to comprehend the research, since informed 
consent requires sufficient time for understanding.17 Also, a once-off 
consent does not constitute consent for the duration of the research 
study, especially if it is long-term, because participants may change 
their mind during the study and may wish to withdraw consent. 
When new information becomes available during the research, this 
must be disclosed to participants for them to reconsider their further 
participation. Therefore, continuous efforts should be made to ensure 
that participants’ wishes regarding continuation are respected.15 Since 
informed consent requires ongoing dialogue between patient and 
health worker, a serious shortcoming is that none of the guidance 
documents we considered contains such provisions.
Consent language
Language barriers are common in a culturally diverse country like 
South Africa, especially with regard to prospective participants’ 
full understanding of technical information.22 Besides potential 
problems with illiterate or uneducated prospective participants, 
their home language (as required by section 2.14 of the ethical 
guidelines) may also differ from the researcher’s. The National 
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Health Act demands that informed consent be obtained in a language 
that users understand and takes into account their literacy level. 
On the other hand, SA GCP 1.2.8 calls for consent to be obtained 
in the participant’s language of choice, which may differ from the 
participant’s home language. Giving participants a language choice 
in which the informed consent must be obtained (verbally and in 
writing) recognises the unique obstacles and needs of multi-lingual 
communities. 
 Ethically and legally, the language used to discuss informed 
consent and the informed consent document must be one that 
participants choose and feel comfortable with rather than insisting 
on their home language. No guidance document clarified whether 
the consent language refers to the verbal discussion or whether the 
written informed consent/assent documents should also be available 
in that language. It has been assumed that consent/assent documents 
should be available in the same language in which the verbal consent 
discussion takes place, but this is not required in the guidance 
documents considered.
Number of signed copies of the 
informed consent document 
The number of signed copies of the informed consent document 
required differs significantly; ICH GCP 5.18.4(e) requires two while 
SA GCP 3.5 requires three. Other research guidance documents and 
the governing legislation do not address this aspect. The GCPs are 
not clear whether a copy refers to an original signed copy, a copy of 
the original signed copy or a certified copy thereof. Legally, according 
to section 221 of the Criminal Procedure Act No 51 of 197723 and 
section 33 of the Civil Proceedings Evidence Act No 25 of 1965,24 only 
one original signed copy of the informed consent document serves 
as the original; all others should be certified by a commissioner of 
oaths. While this is not required by the GCPs and may be impractical 
in clinical research, it is legally futile to require more signed copies 
than the original signed copy. We recommend that if more copies 
are required, e.g. for participant reference, certified copies should 
be made or an unsigned copy given to the participant, because the 
original signed informed consent document must remain at the 
research site. 
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